We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+0.87%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$3.17B
AUM Growth
-$132M
(-4%)
Cap. Flow
+$330M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
55.39%
Holding
52
New
18
Increased
15
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$125M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$110M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$94.8M |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$84.8M |
| 5 |
Exelixis
EXEL
|
+$82.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$680M |
| 2 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
+$76.1M |
| 3 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$54M |
| 4 |
DVAX
Dynavax Technologies
DVAX
|
+$13.5M |
| 5 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
+$2.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$15.8B
| $553M | 17.48% |
4,914,955
+729,613
| +17% | +$94.8M |
|
|
RARX
2
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $233M | 7.37% |
4,858,260
| – | – |
|
|
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $168M | 5.3% |
4,176,910
+977,521
| +31% | +$41.5M |
|
4
Arvinas
ARVN
$540M
| $148M | 4.68% |
3,672,872
| – | – |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $130M | 4.12% |
5,275,538
+3,014,787
| +133% | +$110M |
|
|
6
Axsome Therapeutics
AXSM
$10.7B
| $112M | 3.54% |
1,904,094
+1,536,278
| +418% | +$125M |
|
|
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $106M | 3.35% |
2,162,671
| – | – |
|
8
TG Therapeutics
TGTX
$8.12B
| $102M | 3.23% |
10,387,411
+507,088
| +5% | +$6.4M |
|
|
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $101M | 3.18% |
4,681,858
| – | – |
|
10
Alector
ALEC
$228M
| $99.6M | 3.15% |
4,127,348
+3,127,348
| +313% | +$79.7M |
|
11
Phathom Pharmaceuticals
PHAT
$660M
| $95.7M | 3.02% |
3,707,408
+60,600
| +2% | +$2.03M |
|
12
KALA BIO
KALA
$9.82M
| $95.6M | 3.02% |
4,354
+2,537
| +140% | +$40.5M |
|
13
Rhythm Pharmaceuticals
RYTM
$6.66B
| $82.5M | 2.61% |
5,422,312
| – | – |
|
|
ETNB
14
DELISTED
89bio
ETNB
| $79.8M | 2.52% |
3,161,214
| – | – |
|
|
15
Exelixis
EXEL
$14.1B
| $77.9M | 2.46% |
+4,524,961
| New | +$82.8M |
|
16
Wave Life Sciences
WVE
$879M
| $72.9M | 2.3% |
7,775,207
| – | – |
|
|
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
| $71.1M | 2.24% |
+727,271
| New | +$84.8M |
|
|
MNTA
18
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $68.9M | 2.18% |
2,531,445
+1,085,644
| +75% | +$30.2M |
|
19
Black Diamond Therapeutics
BDTX
$113M
| $64.6M | 2.04% |
+2,589,904
| New | +$78.8M |
|
20
Travere Therapeutics
TVTX
$5.89B
| $60.8M | 1.92% |
4,166,453
-86,000
| -2% | -$1.29M |
|
|
ORTX
21
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $57M | 1.8% |
1,036,466
+397,476
| +62% | +$45.8M |
|
|
IGMS
22
DELISTED
IGM Biosciences
IGMS
| $55.2M | 1.74% |
982,723
| – | – |
|
23
Verastem
VSTM
$665M
| $49.1M | 1.55% |
+1,550,388
| New | +$38.9M |
|
24
Relmada Therapeutics
RLMD
$474M
| $47.1M | 1.49% |
1,379,988
+618,322
| +81% | +$24.9M |
|
25
Gilead Sciences
GILD
$181B
| $41M | 1.29% |
+548,000
| New | +$37.9M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, RA Capital Management held 52 positions worth $3.17B, down 4% from $3.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $330M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Adverum Biotechnologies: 727,271 shares worth $71.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Galera Therapeutics, Inc. Common Stock, an estimated $2.08M trimmed.
- RA Capital Management's largest Q1 2020 buy was Adverum Biotechnologies: 727,271 shares worth $71.1M.
- RA Capital Management added most to Axsome Therapeutics in Q1 2020, an estimated $125M increase.
- RA Capital Management's biggest Q1 2020 reduction was Galera Therapeutics, Inc. Common Stock, cutting an estimated $2.08M.
- RA Capital Management fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $680M.
- RA Capital Management's ten largest holdings make up 55% of its $3.17B portfolio in Q1 2020.
- RA Capital Management opened 18 new positions and closed 4 in Q1 2020.
- RA Capital Management's portfolio value fell 4% quarter-over-quarter to $3.17B.
Based on RA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.